Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rosuvastatin plus ezetimibe vs high-dose rosuvastatin in coronary artery disease without PCI
KCT0009035Phase 4Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, ezetimibe in coronary arteriosclerosis, hypercholesterolemia, sponsored by Hanmi Pharmaceutical. Started Feb 2024; status: recruiting.
02
Drugs
rosuvastatinezetimibe
03
Conditions
coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on KCT0009035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009035.